Effects of lamivudine on the hepatitis B virus specific CD8+ cytotoxic T lymphocyte responses via peptide-MHC tetrameric complexes assay

Tzong Hsien Lee*, Yen Ling Chuang, Sun Lung Tsai, Yun Fan Liaw

*Corresponding author for this work

Research output: Contribution to journalJournal Article peer-review

6 Scopus citations

Abstract

Lamivudine, an oral nucleoside analogue, inhibits hepatitis B virus (HBV) replication. It has been shown to be able to restore T cell responsiveness and to induce a type 1 T helper cell (Th 1) immunity in chronic HBV patients. To further examine the effects of lamivudine on cytotoxic T lmphocyte (CTL) responses, two HBV antigenic peptide-HLA-A2 tetrameric complexes containing peptides derived from HBV core protein (residues 18-27; FLPSDFFPSV) and polymerase (residue 551-559; YMDDVVLGA) were constructed. These two tetramers were used to serially determine the frequency of HBV antigen-specific CD8+ T cells before and during the treatment of lamivudine. The specificity of these tetramers was confirmed by (a) nonstaining of CD8+ T cells from HLA-A2-negative HBV patients, (b) having variable frequency data in the different teteramer measurement, and (c) showing peptide-specific CTL activity in the sorted tetramer-stanining CD8+T cells. Low frequency of HBV-specific CTLs was measured for both tetramers before lamivudine treatment. However, the number of CD8+ T cells specific for HBV core 18-27 increased significantly during lamivudine treatment. In contrast, relatively lower frequency of HBV pol 551-559 specific CD8+ T cells was persistently measured after lamivudine treatment. These results indicated that the lamivudine treatment could enhance HBV specific CTL responses.

Original languageEnglish
Pages (from-to)179-185
Number of pages7
JournalLetters in Peptide Science
Volume8
Issue number3-5
DOIs
StatePublished - 05 2001

Keywords

  • Cytotoxic T lymphocyte response
  • HLA-peptide tetramer complexes
  • Hepatitis B virus
  • Lamivudine

Fingerprint

Dive into the research topics of 'Effects of lamivudine on the hepatitis B virus specific CD8+ cytotoxic T lymphocyte responses via peptide-MHC tetrameric complexes assay'. Together they form a unique fingerprint.

Cite this